JP6679486B2 - 自殺リスクに関連する遺伝子マーカーおよびその使用の方法 - Google Patents

自殺リスクに関連する遺伝子マーカーおよびその使用の方法 Download PDF

Info

Publication number
JP6679486B2
JP6679486B2 JP2016542129A JP2016542129A JP6679486B2 JP 6679486 B2 JP6679486 B2 JP 6679486B2 JP 2016542129 A JP2016542129 A JP 2016542129A JP 2016542129 A JP2016542129 A JP 2016542129A JP 6679486 B2 JP6679486 B2 JP 6679486B2
Authority
JP
Japan
Prior art keywords
subject
suicide
seq
disorder
marker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016542129A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017503493A (ja
JP2017503493A5 (https=
Inventor
ザイ，クレメント・シー
ケネディ，ジェームズ・エル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre for Addiction and Mental Health
Original Assignee
Centre for Addiction and Mental Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre for Addiction and Mental Health filed Critical Centre for Addiction and Mental Health
Publication of JP2017503493A publication Critical patent/JP2017503493A/ja
Publication of JP2017503493A5 publication Critical patent/JP2017503493A5/ja
Application granted granted Critical
Publication of JP6679486B2 publication Critical patent/JP6679486B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C99/00—Subject matter not provided for in other groups of this subclass
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Primary Health Care (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
JP2016542129A 2013-12-23 2014-12-23 自殺リスクに関連する遺伝子マーカーおよびその使用の方法 Active JP6679486B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361920332P 2013-12-23 2013-12-23
US61/920,332 2013-12-23
PCT/CA2014/051257 WO2015095967A1 (en) 2013-12-23 2014-12-23 Genetic markers associated with suicide risk and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2017503493A JP2017503493A (ja) 2017-02-02
JP2017503493A5 JP2017503493A5 (https=) 2018-02-01
JP6679486B2 true JP6679486B2 (ja) 2020-04-15

Family

ID=53477254

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016542129A Active JP6679486B2 (ja) 2013-12-23 2014-12-23 自殺リスクに関連する遺伝子マーカーおよびその使用の方法

Country Status (10)

Country Link
US (1) US10435748B2 (https=)
EP (1) EP3087203B1 (https=)
JP (1) JP6679486B2 (https=)
KR (1) KR20160111925A (https=)
CN (1) CN106062213A (https=)
AU (1) AU2014373588B2 (https=)
CA (1) CA2934815C (https=)
IL (1) IL246417B (https=)
SG (1) SG11201605150YA (https=)
WO (1) WO2015095967A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2891830A1 (en) 2015-05-15 2016-11-15 Centre For Addiction And Mental Health Genetic markers for suicide risk and related methods
US20170312289A1 (en) * 2016-04-29 2017-11-02 Supernus Pharmaceuticals, Inc. Methods, system, and kit for monitoring, diagnosing, and treating impulsive aggression
CN108531569B (zh) * 2017-03-03 2021-05-07 上海伯豪医学检验所有限公司 用于强迫症与精神分裂症、抑郁症甄别的基因标志物及其应用
CN108148905A (zh) * 2018-02-13 2018-06-12 广州市番禺区中心医院(广州市番禺区人民医院、广州市番禺区心血管疾病研究所) 一段可作为抑郁症标记物的序列
EP3975190A4 (en) * 2019-05-23 2023-05-03 Ulsan National Institute of Science and Technology (UNIST) METHOD OF DISCOVERING A MARKER FOR PREDICTING RISK OF DEPRESSION OR SUICIDE USING MULTIOMICS ANALYSIS, MARKERS FOR PREDICTING RISK OF DEPRESSION OR SUICIDE AND METHODS OF PREDICTING RISK OF DEPRESSION OR SUICIDE USING MULTIOMICS ANALYSIS
WO2024215722A1 (en) * 2023-04-10 2024-10-17 Board Of Regents, The University Of Texas System Methods and compositions for diagnosing and treating depression and suicide risk

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USH2191H1 (en) 2000-10-24 2007-06-05 Snp Consortium Identification and mapping of single nucleotide polymorphisms in the human genome
US7361468B2 (en) 2004-07-02 2008-04-22 Affymetrix, Inc. Methods for genotyping polymorphisms in humans
EP2166112B1 (en) * 2008-09-18 2013-06-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Means and methods for diagnosing predisposition for treatment emergent suicidal ideation
CA2736936A1 (en) * 2008-09-18 2010-03-25 Andreas Menke Means and methods for diagnosing predisposition for treatment emergent suicidal ideation (tesi)
KR101249635B1 (ko) * 2010-10-13 2013-04-01 서울대학교산학협력단 양극성 장애 진단용 ｅｇｒ2 유전자 ｓｎｐ, 그를 포함하는 마이크로어레이 및 키트

Also Published As

Publication number Publication date
IL246417B (en) 2020-08-31
EP3087203A4 (en) 2017-09-20
US20170002412A1 (en) 2017-01-05
JP2017503493A (ja) 2017-02-02
CA2934815C (en) 2022-01-04
IL246417A0 (en) 2016-08-31
US10435748B2 (en) 2019-10-08
CA2934815A1 (en) 2015-07-02
SG11201605150YA (en) 2016-07-28
CN106062213A (zh) 2016-10-26
EP3087203A1 (en) 2016-11-02
EP3087203B1 (en) 2019-09-11
AU2014373588A1 (en) 2016-07-21
WO2015095967A1 (en) 2015-07-02
AU2014373588B2 (en) 2021-04-01
KR20160111925A (ko) 2016-09-27

Similar Documents

Publication Publication Date Title
Volpi et al. Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia
Lin et al. Epigenetics and depression: an update
JP6679486B2 (ja) 自殺リスクに関連する遺伝子マーカーおよびその使用の方法
US12006547B2 (en) Detection of chromosome interactions as indicative of amyotrophic lateral sclerosis
JP2020089370A (ja) 抗精神病薬に基づく処置により誘導される錐体外路症状（ｅｐｓ）の発症を予測する方法
WO2012082912A2 (en) Markers related to age-related macular degeneration and uses therefor
CN106834501A (zh) 与中国儿童肥胖相关的单核苷酸多态性位点及其应用
US12612661B2 (en) Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters
Cossée et al. Exonic microdeletions in the X-linked PQBP1 gene in mentally retarded patients: a pathogenic mutation and in-frame deletions of uncertain effect
JP6524073B2 (ja) 抗精神病薬誘導体重増加に関連する遺伝子マーカーおよびその使用のための方法
KR102653468B1 (ko) 단일염기다형성 rs16938619를 포함하는 뇌동맥류 진단 마커
US20230220472A1 (en) Deterimining risk of spontaneous coronary artery dissection and myocardial infarction and sysems and methods of use thereof
US20100129805A1 (en) Slc1a1 antipsychotic drug response markers
CN119859680B (zh) 用于检测SNP位点rs6802921的试剂在制备AMS易感人群筛查产品中的应用
CN103266181B (zh) 一种用于检测ttr基因突变g307c的试剂盒
CN119859681B (zh) 用于检测SNP位点rs2246690的试剂在制备AMS易感人群筛查产品中的应用
Bassil et al. Epigenome-Wide Association Studies in Psychiatry: Achievements and Problems
JP6788879B2 (ja) 末梢動脈疾患検査方法及び検査用試薬
CN105765077B (zh) 测定抗甲状腺药物诱导的粒细胞缺乏症风险的检测方法以及测定用试剂盒
KR20260039156A (ko) 뇌전증 진단용 조성물
Bergen et al. Summaries from the XVIII World Congress of Psychiatric Genetics, Athens, Greece, 3–7 October 2010
KR20250053768A (ko) 회전근개 파열 예측 또는 진단용 조성물, 키트 및 이를 이용한 진단 방법
CN120060466A (zh) 与急性高山病发生相关的人基因组区域1p21.1及其单核苷酸多态性位点的应用
CN106834491B (zh) 乳腺癌预后相关基因突变检测试剂盒及其使用方法
de Jong Network State of Mind

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171211

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20191213

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200303

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200318

R150 Certificate of patent or registration of utility model

Ref document number: 6679486

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250